Evidence map›Paper›PMID 40472634›Full record

ArticleUltrasonics sonochemistry2025

Optimizing energy transfer in NIR ruthenium(II) complexes to enhance stability and efficiency in sonodynamic therapy.

Dazhuang Xu, Qixuan Dai, Jian Sun, Yibo An, Ziying Wang, Lijuan Yang, Zhixiang Lu, Chengchao Chu, Gang Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ultrasonics sonochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dazhuang XuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, Center for Molecular Imaging and Translational Medicine, School of Public Health, Fujian Engineering Research Center of Molecular Theranostic Technology, Xiamen University, Xiamen 361102, China.
Qixuan DaiState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, Center for Molecular Imaging and Translational Medicine, School of Public Health, Fujian Engineering Research Center of Molecular Theranostic Technology, Xiamen University, Xiamen 361102, China.
Jian SunState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, Center for Molecular Imaging and Translational Medicine, School of Public Health, Fujian Engineering Research Center of Molecular Theranostic Technology, Xiamen University, Xiamen 361102, China.
Yibo AnFujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Ziying WangFujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Lijuan YangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, Center for Molecular Imaging and Translational Medicine, School of Public Health, Fujian Engineering Research Center of Molecular Theranostic Technology, Xiamen University, Xiamen 361102, China.
Zhixiang LuFujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China. Electronic address: zhixiangl@xmu.edu.cn.
Chengchao ChuXiamen University affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen 361102, China; The Key Laboratory of Biomedical Imaging Science and System Chinese Academy of Sciences, Shen Zhen Research Institute of Xiamen University Shenzhen 518057, China. Electronic address: chuchengchao@xmu.edu.cn.
Gang LiuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, Center for Molecular Imaging and Translational Medicine, School of Public Health, Fujian Engineering Research Center of Molecular Theranostic Technology, Xiamen University, Xiamen 361102, China; The Key Laboratory of Biomedical Imaging Science and System Chinese Academy of Sciences, Shen Zhen Research Institute of Xiamen University Shenzhen 518057, China. Electronic address: gangliu.cmitm@xmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advancements in nanomedicine have driven the development of multifunctional theranostic platforms for targeted cancer therapy. Sonodynamic therapy (SDT) holds a distinct advantage over traditional photodynamic therapy (PDT) by harnessing ultrasound-triggered sonosensitizer activation, enabling deeper tissue penetration for treating deep-seated tumors. In this study, we present IR780-TPEY-Ru, a nanoplatformspecifically engineered for imaging-guided SDT to address challenges posed by deep-seated tumors. This platform is engineered through the synergistic integration of π-expansive ligands (IR780) with tetraphenylethylene (TPE), yielding a distinct Ru(II) complex that possesses exceptional electronic and structural properties, particularly in the near-infrared (NIR) region. Significant progress has been achieved through the integration of π-expanded tridentate ligands, which facilitate the generation of low-lying intraligand (

Indexed as

Coordination ComplexesEnergy TransferInfrared RaysRutheniumUltrasonic TherapyAnimalsCell Line, TumorDrug StabilityHumansMiceCoordination ComplexesRutheniumNanomedicineNear-infraredSonodynamic therapySonosensitizer

Identifiers

PMID40472634
PMCPMC12171624

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.